Rimon client, ARC Group Acquisition I Corp (the “Company”) announced on May 1 that it closed its initial public offering, selling 12,075,000 units at $10.00 each, including 1,575,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, for total gross proceeds of $120,750,000. Units began trading on the Nasdaq Global Market…

Rimon client, CADV Ventures S.A., an AI software company focused on improving digital customer engagement for large organizations (“CADV.AI”), and Miluna Acquisition Corp (NASDAQ: MMTX) (“Miluna”), a special purpose acquisition company, have announced that they have entered into a definitive business combination agreement. Upon closing of the proposed business combination, the combined company will operate…

Rimon is proud to share that Debbie Klis, partner at Rimon, has been named to EB5 Investors Magazine’s 2025 Top 15 Corporate Attorneys list. The recognition highlights Debbie’s extensive experience across investment funds, securities, and capital markets, with particular depth in advising private equity sponsors, investment firms, and fund managers on complex transactions. Her practice…

Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med”), formerly Cyclacel Pharmaceuticals, Inc., announced the closing of its previously announced Exchange Transaction with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysia-based company specializing in fire safety and protection solutions. The acquisition marks a significant step in Bio Green Med’s diversification,…

Our client, Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines,  has announced that it has entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”)  to acquire its wholly-owned subsidiary, Fitters Sdn. Bhd. a Malaysia-based private limited company formed in 1972, specializing in distributing, trading and…

Rimon is proud to announce that Partner Debbie Klis has been named in the Top 25 Financial Services and Insurance Attorneys of 2025 by Attorney Intel. Attorneys named to the Top 25 list were selected through a methodical process and careful consideration of their career track records and industry contributions. Read the full story on…

Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines,  announced a change in control and leadership on February 26, 2025. Datuk Dr. Doris Wong Sing Ee acquired the majority interest in Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) and will now serve as its Chief Executive Officer and Executive Director. In…

Rimon SPAC client  Arogo Capital Acquisition Corp., announced that it has executed a business combination agreement with Bangkok Tellink Co., Ltd. Bangkok Tellink Co., Ltd. is an emerging leader in advanced telecommunications, mobile network technology, and Internet of Things (IoT) solutions. The transaction is estimated to be valued at USD$350 million and is expected to result…

Rimon is proud to announce that Debbie Klis was recognized in the 2024 Top 15 Corporate Attorneys by EB Investors Magazine. In the EB-5 magazine, EB-5 professionals provide in-depth program information, which is peer-reviewed by an Editorial board. Our EB-5 News Blog also provides thorough, up-to-date EB-5 news articles that cover all recent developments in the…

Rimon Partner Debbie Klis contributed to “What matters the most when selecting an EB-5 project”, published by EB5investors.com . In the blog, Debbie discusses important considerations and risks to be aware of when selecting an EB-5 project from an investment perspective. Read the article here Debbie Klis brings substantial investment fund, securities and capital markets…